Diagnostic Coverage & Reimbursement Conference

 

Securing Coverage & Reimbursement for Diagnostic Tests through Exhibiting Clinical Utility and Cost-Effectiveness to both CMS and Private Payers

 

November 9-10, 2009
Boston, MA

 

With diagnostic tests continuing to increase in complexity and availability, healthcare providers and payers are struck with a tremendous challenge in evaluating and integrating these valuable tests into their practices and payment structures. As tests rapidly emerge on to the market, many products at first glance appear to be very similar to exiting methods of diagnosis, causing a great struggle for diagnostic companies, as they work to exhibit the true value of their products. Reimbursement
of diagnostic tests has become the greatest barrier to integration and commercialization, and is currently a top priority across the industry. Perhaps now more so than ever before, companies must provide exacting data which proves beyond a shadow of a doubt that their product has a greater utility than existing test methods. Whether the test is faster, less expensive or more accurate, these claims must be proven through randomized clinical studies and exacting analysis.

 

Overall, this program will address the challenge of reimbursement in a pragmatic and straightforward manner, allowing for conversation between attendees and a frank dialogue on the challenges that the industry faces. Reimbursement is the number one challenge for in vitro diagnostic companies at this time, and it is a challenge that many executives are being handed who have little or no previous reimbursement experience. Building upon the many successful Q1 medical device and diagnostic
conferences of the past several years, this conference promises to be an enlightening and valuable program for the participants.

 

Key Sessions to Note

Establishing Cohesive Pricing Strategy for New Diagnostic Tests
Christopher Provines, VP of Global Pricing, Reimbursement & Government Affairs Siemens Healthcare

 

Understanding the Role of Clinical Utility in Reimbursement from a Private Payer Perspective
H. Scott Sarran, M.D, Chief Medical Officer, Blue Cross and Blue Shield of Illinois

 

Designing Clinical Studies to Support Diagnostic Product Reimbursement
Dr. David Horwitz, Chief Medical Officer ,Johnson & Johnson Diabetes Institute

 

And Many More...

 

For the full conference agenda, registration details, and information on promotional pricing please contact:

Paul Hernandez, Marketing Manager
phernandez@Q1productions.com
312-602-9684